I'll call back later http://www.bryanslist.net/eroidscom-login-8460.pdf eroids.com down  The ODAC recommendation is based on two Phase II studies of Perjeta in high-risk, HER2-positive early-stage breast cancer, while an ongoing Phase III trial will further evaluate Perjeta in the adjuvant setting (after surgery) and compares Perjeta, Herceptin and chemotherapy with Herceptin and chemotherapy in people with HER2-positive early stage breast cancer. The study has completed enrollment with 4,800 people, and the primary endpoint is invasive disease-free survival; data are expected in 2016.